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Abstract
Pancreatic adenosquamous carcinoma (ASC) is an enigmatic and aggressive tumor that has a 
worse prognosis and higher metastatic potential than its adenocarcinoma counterpart. Here we 
report that ASC tumors frequently harbor somatically acquired mutations in the UPF1 gene, 
which encodes the core component of the nonsense-mediated RNA decay (NMD) pathway. These 
tumor-specific mutations alter UPF1 RNA splicing and perturb NMD, leading to upregulated 
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levels of NMD substrate mRNAs. UPF1 mutations are the first known unique molecular 
signatures of ASC.
There has been little progress in understanding pancreatic ASC since these aggressive 
tumors were first described over a century ago1,2. One problem is that no mutations unique 
to this class of pancreatic tumors have been identified. Thus, while oncogenes and tumor 
suppressor genes have been shown to be altered in ASC—including K-RAS and p53—these 
same genes are also abnormal in other forms of pancreatic cancer3–5. In this communication, 
we report that ASC pancreatic tumors have somatic mutations in Up-frameshift 1 (UPF1), 
which encodes an RNA helicase essential for a highly conserved RNA degradation pathway 
called nonsense-mediated RNA decay (NMD)6. We were initially led to investigate the 
possibility that NMD had a role in ASC because reverse transcription-polymerase chain 
reaction (RT-PCR) analysis showed that an ASC tumor (TU) with wild-type p53 alleles 
expressed an abnormally large band that was not detectable in the adjacent normal pancreas 
(NP) (Supplementary Fig. 1a). Sequence analysis of this large band demonstrated that it was 
generated by alternatively splicing using a non-canonical splice donor in intron 6 and a non-
canonical splice acceptor in intron 10, which both share 14 nt of sequence identity with the 
splice donor (Supplementary Fig. 1b). Quantitative PCR (qPCR) analysis demonstrated that 
the alternatively spliced p53 mRNA was only detectably expressed in tumor tissue, not 
adjacent normal tissue, while the normally spliced p53 mRNA was expressed at similar 
levels in the tumor and adjacent normal tissue (Supplementary Fig. 1c).
The alternative splicing event creating this p53 isoform generates an in-frame premature 
termination codon (PTC) in intron 6 (Supplementary Fig. 1b). Because NMD degrades 
mRNAs with PTCs6,7, the selective accumulation of this “alt-PTC-IVS6-p53” mRNA in the 
tumor tissue but not the adjacent normal tissue, raised the possibility that the tumor tissue 
had deficient NMD. To test this, we screened ASC tumor samples for mutations in core 
NMD genes. We found genomic mutations in the UPF1 gene in ASC tumors from 18 of 23 
patients (see TU in Fig. 1a), whereas the 3 other NMD genes we tested—UPF2, UPF3A, 
and UPF3B—did not have detectable mutations (Supplementary Table 1). The UPF1 
mutations were somatic in origin, since they were not present in matched normal pancreatic 
tissues from these 18 patients (see NP in Fig. 1a). UPF1 mutations were also not present in 
50 non-ASC pancreatic and SCC lung tumors that we tested (Supplementary Table 2). 
Together, these results suggest that UPF1 mutations are a unique signature of ASC 
pancreatic tumors.
The point mutations in the ASC tumors clustered in two regions of the UPF1 gene (Fig. 1b). 
Surprisingly, these mutations were nearly equally distributed in the exons and introns in 
these two regions. This raised the possibility that they alter UPF1 splicing by disrupting 
intronic splicing enhancers (ISEs) and exonic splicing enhancers (ESEs), which are essential 
for the inclusion of a subset of exons during splicing8,9. In support of this, a subset of the 
mutations in the ASC tumors disrupted predicted ESEs/ISEs (Fig. 1b and Supplementary 
Fig. 2). To directly test whether the ASC mutations disrupt UPF1 splicing, we generated 
UPF1 mini-gene constructs corresponding to the two regions mutated in ASC tumors (Fig. 
2a,b). We then introduced, by site-specific mutagenesis, the mutations found in 15 of the 
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patients. Transfection analysis showed that the wild-type versions of the two mini-gene 
constructs expressed normally spliced mRNA that included all exons, as determined by 
direct sequencing of the bands generated by RT-PCR (Fig. 2c,d). No other bands were 
detected, indicating that most of the mature mRNA generated by these mini-gene constructs 
was normally spliced. In contrast, all 15 mutant mini-genes expressed alternatively spliced 
transcripts (Fig. 2,d). While none of the patient’s mutations completely eliminated normal 
splicing, the ratio of alternatively spliced-to-normally spliced mRNA was 10 to 1 or higher 
in many cases. As confirmation, analysis of endogenous UPF1 splicing in 2 of 2 frozen 
tumor samples revealed an alternatively spliced UPF1 mRNA that was not present in the 
adjacent normal tissue (Fig. 2e). We conclude that ASC-specific mutations in the UPF1 
gene trigger alternative splicing of UPF1 pre-mRNA.
The UPF1 alternative splicing events caused by mutations in the exon 10/11 region 
eliminate a portion of UPF1’s RNA helicase domain essential for UPF1 function6, while 
mutations in the exon 21/23 region truncate the carboxy-terminal region of UPF1, which 
contains [S/T]Q motifs phosphorylated by SMG1, a serine/threonine kinase required for 
NMD10 (Figs. 1b and 2c). Given that essential UPF1 domains are lost, these mutant forms of 
UPF1 are likely to have lost their function or have dominant-negative activity. In the case of 
the latter, inhibited NMD would be predicted to occur when only one UPF1 allele is 
mutated. In support of this possibility, mutations in various regions of UPF1 have previously 
been shown to confer dominant-negative activity11–13. With regard to the former, we found 
that at least one ASC tumor (from patient 22) had mutations in both UPF1 alleles. Several 
other ASC tumors have multiple UPF1 mutations (Supplementary Table 1), consistent with 
some of them also having mutations in both UPF1 alleles. In further support of this notion, 
we observed little or no UPF1 expression in many ASC tumors compared to adjacent normal 
tissue, as demonstrated by immunohistochemical (IHC) analysis (Fig. 2f and Supplementary 
Table 1). As direct evidence that NMD is inhibited in ASC tumors, we found that the NMD 
substrates, ATF3 and MAP3K14 mRNA14, were dramatically upregulated in tumor tissue 
relative to adjacent normal tissue (Supplementary Fig. 3).
Since perturbation of NMD is known to dysregulate ~3 to 10% of mRNAs in a variety of 
cell lines and organisms6,14,15, it is likely this will also be the case of ASC tumors, which 
could shift the balance towards a more malignant phenotype16,17. One candidate NMD 
substrate that could serve in this capacity is the alternatively spliced p53 transcript—alt-
PTC-IVS6-p53—that we identified above (Supplementary Fig. 1), as we found it encoded a 
protein with dominant-negative activity (Supplementary Fig. 4).
The discovery of mutations in the UPF1 gene in ASC tumors represents the first known 
example of genetic alterations in a NMD gene in human tumors. To our knowledge, UPF1 is 
also the first gene known to be selectively mutated in pancreatic ASC tumors. Other genes 
mutated in these tumors, including p53 and K-RAS (see Supplementary Fig. 5 and 
Supplementary Table 1) are also mutated in other pancreatic tumor types4,5. We note that it 
is possible that UPF1 mutations in ASC tumors have broad disruptive effects that that 
extend beyond NMD, including Staufen-mediated RNA decay18. Our finding that UPF1 is 
selectively mutated in pancreatic ASC suggests that this feature will be useful for diagnosis 
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of this type of tumor and also raises the possibility that ASC patients can benefit from 
therapy designed to target NMD substrates19,20.
METHODS
Methods are available in the Supplementary Information section.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Somatic UPF1 mutations in ASC tumors. (a) Chromatograms of UPF1 DNA sequences 
from tumor (TU) and normal adjacent pancreatic tissue (NP). A total of 36 single-base 
substitutions in genomic UPF1 DNA were found in the tumors; each patient had between 
one to five point mutations. All NP samples had wild-type UPF1 sequences, indicating 
mutations were somatic in origin. (b) Top: schematic of UPF1 protein domains. Bottom: the 
type and location of mutations found in the two regions of UPF1 that harbored mutations. 
ESEs and ISEs are exonic and intronic splicing enhancers, respectively (sequences are 
provided on Supplementary Figure 2).
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ASC-specific UPF1 mutations trigger alternative UPF1 RNA splicing. (a) The indicated 
region of human UPF1 (nt 22,779-23,570, RefSeq accession number NC_000019.9) was 
cloned into the NdeI site of the pTBNde mini-gene construct. All mutations were generated 
by site-directed mutagenesis to match those in the indicated patient’s tumors. (b) The 
indicated region of human UPF1 (nt 33,138-34,490) was cloned and mutated as described in 
panel a. (c) RT-PCR analysis of HEK293 cells transfected with the constructs shown in 
panel a (primer locations are indicated by the arrows). Direct sequencing of the large (792 
nt) and small (239 nt) bands indicated that they correspond to normally spliced and exon-
skipped transcripts, respectively. The numbers below the gel are the average values from 
five independent transfections. (d) RT-PCR analysis performed as in panel c. Direct 
sequencing of the bands in the gel indicated they were derived from mRNA spliced in the 
manner shown in the schematic. The bands corresponding to normally spliced, alt 1, and alt 
2 mRNA had lengths of 742, 1117, and 619 nt, respectively. The numbers below the gel are 
the average values from five independent transfections. (e) RT-PCR analysis of normal 
pancreas (NP) and ASC frozen samples (TU) from patients 15 and 16. RT-PCR sequencing 
results are indicated as schematics next to the gels. (f) Immunohistochemical analysis of 
UPF1 staining in ASC tumor samples from patient 15. Tumor (T) and normal tissue (NT) 
are indicated. Bottom panel shows H & E staining, with arrows pointing to the 
adenocarinoma component in this ASC tumor. The scale bar represents 200 micrometers on 
each picture.
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